市場調查報告書
商品編碼
1123059
呼吸系主導療藥及設備的全球市場:2022-2028年Global Respiratory Drugs and Devices Market Research and Forecast, 2022-2028 |
全球呼吸系主導療藥及設備的市場規模在預測期間內預計以7.2%的年複合成長率成長。
生活方式的變化和肥胖率增加牽引該市場。還有抽煙率高,都市化的發展,污染度的上升為市場成長也估計是有大幅貢獻的要素。同時,新興國家的償付不足和認知度有限,低可用性等成為妨礙市場成長的主要原因。
本報告提供全球呼吸系主導療藥及設備的市場調查,市場概要,市場成長的各種影響因素分析,市場規模的變化、預測,各種區分、各地區/主要國家的明細,競爭環境,主要企業簡介等彙整資訊。
Global Respiratory Drugs and Devices Market Research By Product (Respiratory Therapeutic Devices, Respiratory Diagnostic and Monitoring Devices, and Respiratory Consumables and Accessories Meters), By Respiratory Drugs (Respiratory Drugs by Route of Administration and Respiratory Drugs by Drug Class), and By End-Users (Hospitals, Home Care and Other End-Users) Forecast 2021-2027
The global respiratory drugs and devices market is growing at a CAGR of 7.2% during the forecast period. Changing lifestyle and the growing rate of obesity is considered as the prime factors affecting and driving the market. Additionally, the high frequency of people smoking, increase in urbanization along with the rising level of pollution, are also estimated to be the major factors that are contributing significantly towards the growth of the market. However, the unfavorable scenarios in reimbursement and limited awareness and availability in emerging markets are the major factors constraints that are hindering the growth of the global respiratory drugs and devices market across the globe.
Moreover, the growing demand for remote monitoring and home care products are the key factors that are creating opportunities in the market. New product launches and collaboration in the market are likely to drive the growth of the global respiratory drugs and devices. For instance, in July 2020, Novartis AG had put forward the results from the second phase IRIDIUM study. This study result indicates that one daily treatment dose which is high and medium of enerzair; breezhaler had highlighted the improvement in the functionality of lung along with asthma.
Impact of COVID-19 on the Global Respiratory Drugs and Devices Market
The global respiratory drug and device market is hardly hit by the COVID-19 pandemic since December 2019. The COVID-19 pandemic in the major economies had disrupted manufacturing and transportation activities. However, with the lockdown restriction lifted it is likely to increase the output for respiratory drug devices for supporting the patients.
Segmental Outlook
The market is segmented based on product, respiratory drugs, and end-users. By product, the market is segmented into respiratory therapeutic devices, respiratory diagnostic and monitoring devices, respiratory consumables, and accessories meters. Further, the respiratory drug is segmented into respiratory drugs by route of administration and respiratory drugs by drug class. Based on end-users hospitals, home care, and other end-users.
Global Respiratory Drugs and Devices Market by Respiratory, 2020 (%)
Global Respiratory Drugs and Devices Market by Respiratory
Based on the product, respiratory therapeutic devices hold a significant share in the market. These devices are owing to be utilized in order to improve pulmonary function, enhance lung oxygenation, along with providing support for the removal of mucus from the bronchi during respiratory therapy. Additionally, the rising pervasiveness of smoking and growing susceptibility to accidents and airborne infections that cause various injuries such as chest and nasal which can lead to respiratory problems is also supporting in increasing the demand for therapeutic respiratory devices.
Regional Outlooks
Global respiratory drugs and devices market is analyzed on the basis of the geographical regions that are contributing significantly towards the growth of the market. Based on the geography, the market is divided into North America, Europe, Asia Pacific, and Rest of the World. North America is estimated to be the leading region in the global respiratory drugs and devices market. Increasing in respiratory diseases and disorders is also one of the major factors driving the growth of the market in the region. Additionally, leading manufactures and players are present in the region along with technological advancement that are some other factors that are promoting the growth of the market.
Global Respiratory Drugs and Devices Market Growth, by Region 2021-2027
Global Respiratory Drugs and Devices Market Growth, by Region
Asia-Pacific will have Considerable Growth in the Global Respiratory Drugs and Devices Market
The Asia-Pacific region is regarded as the economies to grow and is expected to create an opportunity for market of global respiratory drugs and devices market. The rising incidence of chronic respiratory diseases such as asthma and COPD is also one of the major factors for the growth of the market in the Asia-Pacific region. Further, the market is driven by increasing urbanization along with pollution levels is another factor that is supporting the growth of the market in the region.
Market Players Outlook
Key companies in the global respiratory drugs and devices market include AstraZeneca, Bayer AG, Ge Healthcare Ltd., GlaxoSmithKline, and Novartis AG among others. To survive in the market, these players adopt different marketing strategies such as product launches and mergers and acquisitions. For instance, in November 2021, ALung Technologies had received the approval from FDA for its Hemolung respiratory support platform. This platform is designed in such a manner that in order to provides low-flow extracorporeal carbon dioxide removal (ECCO2R) for patients with acute respiratory failure.
In June 2021, Teva Pharmaceuticals had introduced the first generic version of twice-daily PERFOROMIST, formoterol fumarate inhalation solution, 20 mcg/2 ML, in the US for the purpose of providing treatment to patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
In November 2020, Philips had introduced a non-invasive ventilator that is BiPAP A40 in order to remotely monitor patients suffering from a chronic obstructive pulmonary disease (COPD) along with support them to breathe conveniently.
In September 2020, Boehringer Ingelheim International GmbH announced the launch of the first FDA-approved inhalant therapy that is Aservo Equihaler for horses suffering from equine asthma.
In September 2020, Invacare Corp., one of the leading manufacturers and distributors of medical equipment had introduced a new oxygen concentrator in order to address the rising global demand for respiratory equipment.
The Report Covers
Market value data analysis of 2021 and forecast to 2027.
Annualized market revenues ($ million) for each market segment.
Country-wise analysis of major geographical regions.
Key companies operating in the global respiratory drugs and devices market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
Analysis of market-entry and market expansion strategies.
Competitive strategies by identifying 'who-stands-where' in the market